Actifuse is a new class of synthetic bone graft from ApaTech. Combining an optimized osteoconductive scaffold with unique chemical properties, Actifuse creates the optimal synthetic graft for facilitating rapid and sustained bone ingrowth.
A Unique Product Chemistry - Silicate Substituted Calcium Phosphate
ApaTech research has focused on uniting an optimized physical scaffold with a novel chemical formulation to manufacture an optimized synthetic bone graft.
The result of this extensive research is Actifuse, a new class of synthetic bone graft. Actifuse is a unique bone graft material in which silicate ions have selectively replaced phosphate groups in the calcium phosphate lattice. This silicate substitution creates a material that promotes rapid formation of bone and increases the volume of bone formed in the graft/host bone composite structure. Macro- and microporosity allows newly forming bone and capillary blood vessels to grow throughout the network of interconnecting pores. Unlike many synthetic bone graft products, Actifuse retains its three-dimensional structure until bone repair is achieved.
The Effect of Silicate on Bone Formation
Actifuse is a phase-pure 80% porous calcium phosphate material in which the phosphate groups are selectively replaced with silicate ions. Studies have shown that silicon is a significant dietary trace element for healthy bone formation and remodeling. Silicon, released in vivo, is reported to enhance osteoblastic differentiation and stimulate the formation of bone tissue. Moreover the surface chemistry of Actifuse leads to enhanced adsorption and activation of the proteins involved in osteogenesis, leading to much more rapid and better quality bone formation than with traditional synthetic bone graft materials.
Exceptional Bone Growth Speed and Volume
The presence of silicate in the Actifuse lattice structure enhances the speed and volume of bone ingrowth. Studies have shown that Actifuse, with its silicate substituted chemistry, forms mature lamellar bone at earlier time points than traditional synthetic bone graft substitutes. Furthermore, histology of the Actifuse implant shows extensive remodeling of the new trabecular network, thus improving the organization and strength of the host bone/graft composite structure.
A Unique Product Chemistry - Silicate Substituted Calcium Phosphate
ApaTech research has focused on uniting an optimized physical scaffold with a novel chemical formulation to manufacture an optimized synthetic bone graft.
The result of this extensive research is Actifuse, a new class of synthetic bone graft. Actifuse is a unique bone graft material in which silicate ions have selectively replaced phosphate groups in the calcium phosphate lattice. This silicate substitution creates a material that promotes rapid formation of bone and increases the volume of bone formed in the graft/host bone composite structure. Macro- and microporosity allows newly forming bone and capillary blood vessels to grow throughout the network of interconnecting pores. Unlike many synthetic bone graft products, Actifuse retains its three-dimensional structure until bone repair is achieved.
The Effect of Silicate on Bone Formation
Actifuse is a phase-pure 80% porous calcium phosphate material in which the phosphate groups are selectively replaced with silicate ions. Studies have shown that silicon is a significant dietary trace element for healthy bone formation and remodeling. Silicon, released in vivo, is reported to enhance osteoblastic differentiation and stimulate the formation of bone tissue. Moreover the surface chemistry of Actifuse leads to enhanced adsorption and activation of the proteins involved in osteogenesis, leading to much more rapid and better quality bone formation than with traditional synthetic bone graft materials.
Exceptional Bone Growth Speed and Volume
The presence of silicate in the Actifuse lattice structure enhances the speed and volume of bone ingrowth. Studies have shown that Actifuse, with its silicate substituted chemistry, forms mature lamellar bone at earlier time points than traditional synthetic bone graft substitutes. Furthermore, histology of the Actifuse implant shows extensive remodeling of the new trabecular network, thus improving the organization and strength of the host bone/graft composite structure.
Actifuse Outperforms â-TCP and Traditional Hydroxyapatite Synthetic Bone Graft Materials
Research data shows that Actifuse outperforms traditional hydroxyapatite and â-tri-calcium phosphate scaffolds in terms of the rate of new bone formation, the quantity of bone developed, and its quality. Although autograft is a common source of bone graft, and generally considered the "Gold Standard" among bone graft materials, it is associated with a number of clinical issues, including donor site pain and complications. Actifuse provides surgeons with a safe alternative to autograft.
Actifuse Matches Autograft
Autograft is a common source of bone graft, and generally considered the Gold Standard among bone graft materials. However it is associated with a number of clinical issues, including donor site pain and complications. Actifuse, when tested in a standard pre-clinical model of spinal fusion, demonstrated equivalence on all parameters, including fusion mass, biomechanical performance and radiographic evidence of fusion, to autograft. Thus Actifuse may provide surgeons with a safe alternative to autograft.
Optimal Handling and Placement
The unique granular structure of Actifuse, when combined with localized blood or in combination with blood marrow aspirate, in a ration of 1-1.5:1 (blood/BMA to Actifuse) allows for optimal handling and placement characteristics. Actifuse is a chemically unified implant that acts within the defect site, addressing concerns about possible remote effects associated with bioactive agents.
Sterile, Synthetic, Disease-free
Actifuse is completely synthetic and therefore free of human pathogens. This means that there is zero risk from infection due to inadvertent transfer of human or animal infective agents, such as HIV, hepatitis, and CJD. Sterility is ensured by time-tested medical product irradiation processes.
Indications for Use: Europe & Australia
Bone graft substitutes are intended to be used in place of cortico-cancellous, or cancellous allograft or autograft bone.
The mechanical environment for such uses experiences either low load requirements or compression.
Typical surgical applications for bone graft substitutes are:
Small void filling, e.g. after removal of a small bone tumour or following bone fracture reduction or in osteotomies and plastic surgery.
Spinal fusion, where a cage or screw fixation device is used to relieve the graft site from physiological loads.
It is not intended to be used in place of cortical strut allograft bone where high tensile, torsion and/or bending strength are required.
Your Choice
Actifuse is a major advance in the technology of synthetic bone grafting materials. Its unique combination of an osteoconductive scaffold with exceptional chemical properties provides rapid and high volume bone ingrowth, leading to integrated bone repair.
